Literature DB >> 22199667

Methyl 5-chloro-2-nitro-benzoate.

Yan-Shu Liang, Bing-Ni Liu, Mo Liu, Deng-Ke Liu.   

Abstract

In the title compound, C(8)H(6)ClNO(4), the nitro and acet-oxy groups attached to the benzene ring at neighbouring positions are twisted from its plane by 29.4 (1) and 49.7 (1)°, respectively. In the crystal, weak C-H⋯O hydrogen bonds link mol-ecules into layers parallel to (101). The crystal packing exhibits short inter-molecular C⋯O distances of 2.925 (3) Å.

Entities:  

Year:  2011        PMID: 22199667      PMCID: PMC3238814          DOI: 10.1107/S1600536811044072

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

The title compound is an inter­mediate of the oral vasopressin V2-receptor antagonist tolvaptan. For applications of tolvaptan, see: Nemerovski & Hutchinson (2010 ▶). For the synthesis of the title compound, see: Kondo et al. (1999 ▶). For a related structure, see: Liu et al. (2008 ▶).

Experimental

Crystal data

C8H6ClNO4 M = 215.59 Monoclinic, a = 4.2616 (9) Å b = 22.470 (5) Å c = 9.3894 (19) Å β = 90.64 (3)° V = 899.1 (3) Å3 Z = 4 Mo Kα radiation μ = 0.41 mm−1 T = 113 K 0.16 × 0.14 × 0.12 mm

Data collection

Rigaku Saturn diffractometer Absorption correction: multi-scan (CrystalClear; Rigaku/MSC, 2005 ▶) T min = 0.937, T max = 0.952 5007 measured reflections 1564 independent reflections 1400 reflections with I > 2σ(I) R int = 0.031

Refinement

R[F 2 > 2σ(F 2)] = 0.041 wR(F 2) = 0.116 S = 1.07 1564 reflections 128 parameters H-atom parameters constrained Δρmax = 0.27 e Å−3 Δρmin = −0.27 e Å−3 Data collection: CrystalClear (Rigaku/MSC, 2005 ▶); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: SHELXTL (Sheldrick, 2008 ▶); software used to prepare material for publication: SHELXTL. Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536811044072/cv5162sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536811044072/cv5162Isup2.hkl Supplementary material file. DOI: 10.1107/S1600536811044072/cv5162Isup3.cdx Supplementary material file. DOI: 10.1107/S1600536811044072/cv5162Isup4.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C8H6ClNO4F(000) = 440
Mr = 215.59Dx = 1.593 Mg m3
Monoclinic, P21/nMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2ynCell parameters from 2662 reflections
a = 4.2616 (9) Åθ = 1.8–27.5°
b = 22.470 (5) ŵ = 0.41 mm1
c = 9.3894 (19) ÅT = 113 K
β = 90.64 (3)°Prism, colorless
V = 899.1 (3) Å30.16 × 0.14 × 0.12 mm
Z = 4
Rigaku Saturn diffractometer1564 independent reflections
Radiation source: rotating anode1400 reflections with I > 2σ(I)
confocalRint = 0.031
ω scansθmax = 25.0°, θmin = 2.4°
Absorption correction: multi-scan (CrystalClear; Rigaku/MSC, 2005)h = −4→5
Tmin = 0.937, Tmax = 0.952k = −26→20
5007 measured reflectionsl = −11→11
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.041Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.116H-atom parameters constrained
S = 1.07w = 1/[σ2(Fo2) + (0.0708P)2 + 0.3934P] where P = (Fo2 + 2Fc2)/3
1564 reflections(Δ/σ)max = 0.001
128 parametersΔρmax = 0.27 e Å3
0 restraintsΔρmin = −0.27 e Å3
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
Cl10.83432 (12)0.09111 (2)1.09984 (5)0.0272 (2)
O10.1416 (4)0.05968 (8)0.42100 (17)0.0423 (5)
O2−0.1876 (4)0.12282 (9)0.48951 (17)0.0409 (5)
O30.1575 (4)0.22747 (7)0.57507 (16)0.0364 (4)
O4−0.0357 (3)0.22861 (6)0.78230 (15)0.0263 (4)
N10.0553 (5)0.09256 (8)0.51178 (19)0.0282 (5)
C10.2555 (5)0.09452 (9)0.6557 (2)0.0224 (5)
C20.4194 (5)0.04329 (9)0.7038 (2)0.0273 (5)
H20.41480.00920.64780.033*
C30.6002 (5)0.04214 (9)0.8420 (2)0.0263 (5)
H30.70410.00770.87070.032*
C40.6111 (5)0.09270 (8)0.9265 (2)0.0215 (5)
C50.4463 (5)0.14420 (9)0.8781 (2)0.0224 (5)
H50.45190.17830.93420.027*
C60.2642 (5)0.14566 (9)0.7406 (2)0.0218 (5)
C70.1199 (5)0.20438 (9)0.6857 (2)0.0228 (5)
C8−0.1662 (6)0.28749 (10)0.7466 (2)0.0323 (5)
H8A0.00170.31570.73730.049*
H8B−0.30390.30010.82090.049*
H8C−0.28140.28500.65840.049*
U11U22U33U12U13U23
Cl10.0369 (4)0.0243 (3)0.0204 (3)0.0011 (2)−0.0024 (2)0.00056 (18)
O10.0641 (13)0.0388 (10)0.0241 (9)0.0017 (8)0.0011 (8)−0.0105 (7)
O20.0322 (10)0.0596 (12)0.0308 (9)0.0044 (8)0.0003 (7)0.0013 (8)
O30.0481 (10)0.0359 (9)0.0256 (9)0.0124 (7)0.0201 (7)0.0125 (7)
O40.0334 (9)0.0244 (8)0.0215 (8)0.0032 (6)0.0139 (6)0.0031 (6)
N10.0335 (11)0.0305 (10)0.0206 (10)−0.0064 (8)0.0023 (8)0.0002 (8)
C10.0231 (11)0.0270 (11)0.0174 (11)−0.0047 (8)0.0048 (8)−0.0011 (8)
C20.0352 (12)0.0223 (10)0.0246 (11)−0.0058 (9)0.0087 (9)−0.0063 (8)
C30.0331 (12)0.0209 (10)0.0252 (12)−0.0008 (9)0.0071 (9)0.0024 (8)
C40.0255 (11)0.0217 (10)0.0176 (10)−0.0033 (8)0.0055 (8)0.0018 (8)
C50.0280 (11)0.0215 (10)0.0178 (10)−0.0035 (8)0.0100 (8)−0.0003 (8)
C60.0229 (11)0.0252 (10)0.0175 (10)−0.0030 (8)0.0099 (8)0.0020 (8)
C70.0242 (10)0.0258 (10)0.0186 (11)−0.0017 (8)0.0049 (8)−0.0004 (8)
C80.0416 (14)0.0250 (11)0.0307 (13)0.0076 (10)0.0123 (10)0.0038 (9)
Cl1—C41.876 (2)C2—H20.9300
O1—N11.189 (2)C3—C41.386 (3)
O2—N11.254 (3)C3—H30.9300
O3—C71.174 (2)C4—C51.425 (3)
O4—C71.254 (2)C5—C61.500 (3)
O4—C81.472 (3)C5—H50.9300
N1—C11.590 (3)C6—C71.542 (3)
C1—C61.399 (3)C8—H8A0.9600
C1—C21.418 (3)C8—H8B0.9600
C2—C31.502 (3)C8—H8C0.9600
C7—O4—C8115.29 (16)C4—C5—C6122.73 (18)
O1—N1—O2118.6 (2)C4—C5—H5118.6
O1—N1—C1117.30 (18)C6—C5—H5118.6
O2—N1—C1124.10 (17)C1—C6—C5118.89 (18)
C6—C1—C2118.4 (2)C1—C6—C7120.30 (18)
C6—C1—N1121.16 (18)C5—C6—C7120.47 (17)
C2—C1—N1120.40 (17)O3—C7—O4121.8 (2)
C1—C2—C3122.38 (18)O3—C7—C6128.04 (18)
C1—C2—H2118.8O4—C7—C6110.01 (16)
C3—C2—H2118.8O4—C8—H8A109.5
C4—C3—C2119.62 (19)O4—C8—H8B109.5
C4—C3—H3120.2H8A—C8—H8B109.5
C2—C3—H3120.2O4—C8—H8C109.5
C3—C4—C5118.0 (2)H8A—C8—H8C109.5
C3—C4—Cl1119.63 (16)H8B—C8—H8C109.5
C5—C4—Cl1122.36 (15)
O1—N1—C1—C6152.58 (19)N1—C1—C6—C5177.54 (15)
O2—N1—C1—C6−28.3 (3)C2—C1—C6—C7173.45 (17)
O1—N1—C1—C2−30.1 (3)N1—C1—C6—C7−9.2 (3)
O2—N1—C1—C2149.0 (2)C4—C5—C6—C1−0.1 (3)
C6—C1—C2—C30.1 (3)C4—C5—C6—C7−173.43 (18)
N1—C1—C2—C3−177.31 (16)C8—O4—C7—O30.0 (3)
C1—C2—C3—C4−0.4 (3)C8—O4—C7—C6175.57 (17)
C2—C3—C4—C50.4 (3)C1—C6—C7—O3−48.6 (3)
C2—C3—C4—Cl1179.53 (14)C5—C6—C7—O3124.6 (2)
C3—C4—C5—C6−0.1 (3)C1—C6—C7—O4136.20 (19)
Cl1—C4—C5—C6−179.27 (14)C5—C6—C7—O4−50.6 (2)
C2—C1—C6—C50.2 (3)
D—H···AD—HH···AD···AD—H···A
C2—H2···O1i0.932.533.206 (3)130.
C8—H8B···O3ii0.962.473.200 (3)132.
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C2—H2⋯O1i0.932.533.206 (3)130
C8—H8B⋯O3ii0.962.473.200 (3)132

Symmetry codes: (i) ; (ii) .

  4 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

Authors:  K Kondo; H Ogawa; H Yamashita; H Miyamoto; M Tanaka; K Nakaya; K Kitano; Y Yamamura; S Nakamura; T Onogawa; T Mori; M Tominaga
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

Review 3.  Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.

Authors:  Carrie Nemerovski; David J Hutchinson
Journal:  Clin Ther       Date:  2010-06       Impact factor: 3.393

4.  Methyl 4-chloro-3-nitro-benzoate.

Authors:  Bo-Nian Liu; Shi-Gui Tang; Hao-Yuan Li; Ye-Ming Xu; Cheng Guo
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.